Communicators

Herzeliya, Israel and Calgary, Alberta,( May 1, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has announced today that the Management of InnoCan has appointed  Prof. Daniel Offen, of the Sackler School of Medicine, Sagol School of Neuroscience at Tel Aviv University,  to its Scientific Advisory Committee.

Recently, on April 17th InnoCan announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has entered into a sponsored research agreement dated April 17, 2020 (the “Research Agreement”) with Ramot at Tel Aviv University (“Ramot”)  to collaborate with Tel Aviv university to develop a novel, revolutionary approach to treat COVID-19 by using cannabidiol (CBD) loaded exosomes (“CLX”).

Professor Daniel Offen is a Full professor at Dept. of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine. Sagol School of Neuroscience, Tel Aviv University.

Prof. Offen studied molecular biology, at the Weizmann Institute of Science, Israel. He furthered his education at the Albert Einstein College of Medicine, NY, USA, as a Post-Doctoral Fellow.

His work has concentrated on cell and gene therapy in neurodegenerative diseases. Offen published over 200 articles, review papers and book chapters and had file over 30 granted patents.

Prof. Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics ( NASDAQ # BCLI), developed cell treatment for ALS patients, and is now in Phase III clinical trial.

Prof. Offen states: "I am glad to join the scientific advisory committee of InnoCan Pharma. We, InnoCan Pharma and the University of Tel Aviv are joining the forces now to develop, what we expect to be, a revolutionary approach to fight multiple diseases. Based on my personal experience, I feel that our approach treating COVID-19 disease with a combination of exosomes and CBD molecules hold a great potential. Each component itself has its own potential to treat the impact of the virus in the human body." And he further comments: "Exosomes research is a relatively new field in the stem cell sector. Yoram Drucker, and I worked together establishing Brainstorm Cell Therapeutics  and he is one of the founders of Pluristem Therapeutics Inc. another NASDAQ listed stem cell biotech company. Yoram brings his experience in the stem cell area and I am glad to be a part of the Team now."

Yoram Drucker, Founder and VP Business Development of InnoCan: "The partnership of Innocan and Prof. Offen is an important milestone in the history of our company. Our idea to combine very new stem cell technology with well-known effects of CBD and the highly experienced team of Prof. Offen found open ears at the University of Tel Aviv. We can't wait to start and see first results which considered to support our theory." 

About InnoCan Pharma Corporation

The Company, through its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Pharma Israel"), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD"). InnoCan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, whichh is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed on a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For InnoCan Pharma Corporation:

Iris Bincovich, CEO

+972-54-3012842

info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond InnoCan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the product markets, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in InnoCan's public reports and filings which are available under InnoCan's profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. InnoCan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events